Other Oncology.TV sites:

  • Home
  • Continuing Education
  • Oncology TV Network
  • Ask The Experts
  • Symptom Management
  • Events
  • Links
Login | Register
Oncology TV – Your Peer Network
The Oncology TV Network is a way to learn and interact with your peers. Please submit a question regarding the current video playing (“Ask the Experts”) to find out more about this topic. 

For additional information about this and related topics, please visit our partner sites at MPNUniversity.TV. (www.mpnuniversity.tv) and SCUniversity.TV (www.scuniversity.tv)

Please select a video from the list below.
Immunotherapy for GI Cancer
The following program was filmed at "Fighting a Smarter War Against Cancer", a Symposium presented by The Ruesch Center for the Cure of Gastrointestinal Cancers. Presented by Joe Leveque, MD, Chief Medical Officer at EMD Sereno, Inc.
  • Slide deck: Immunotherapy in GI Cancer
Ask the Experts
Use the space below to submit your questions to the Oncology.TV Experts. (Login required.)
Question:

 
Email Address:

 
progress Please wait....Submitting your Question!
Related Questions
No related Ask The Experts Q&A available.
Recent Video
| 
Most Popular
Specialties :                    Search :
Identifying Signs of Sepsis: Challenges in Implementing Sepsis Core Measure
Identifying Signs of Sepsis: Challenges in Implementing Sepsis Core Measure Views - 16
Pharmacology Update in Oncology: 2017
Pharmacology Update in Oncology: 2017 Views - 10
Low Health Literacy and Cancer Survivorship: We
Low Health Literacy and Cancer Survivorship: We've Got Some Explaining to Do Views - 8
The Terror of Cancer: The View from the Other Side of the Hospital Gown
The Terror of Cancer: The View from the Other Side of the Hospital Gown Views - 7
Care Coordination: Managing the Needs of the Complex, Chronically Ill Patient
Care Coordination: Managing the Needs of the Complex, Chronically Ill Patient Views - 8
LGBTQ Savvy: Law, Policy, and Diversity
LGBTQ Savvy: Law, Policy, and Diversity Views - 7
Medical Marijuana: It
Medical Marijuana: It's Not How High, But How Far We Can Go Views - 6
Impact of Patient Reported Symptoms on Physical Function and Quality of Life in Adults with Acute Leukemia
Impact of Patient Reported Symptoms on Physical Function and Quality of Life in Adults with Acute Leukemia Views - 6
Neuropathic Pain in Cancer Patients: The use of Multimodal Therapy to Increase Success
Neuropathic Pain in Cancer Patients: The use of Multimodal Therapy to Increase Success Views - 4
Sickle Cell Disease Pain Management
Sickle Cell Disease Pain Management Views - 9
Immunotherapy - Psychosocial & Educational Considerations and Resources
Immunotherapy - Psychosocial & Educational Considerations and Resources Views - 6
Immunotherapy - Oncolytic Viral Therapies - Overview and Clinical Applications
Immunotherapy - Oncolytic Viral Therapies - Overview and Clinical Applications Views - 4
Immunotherapy - Checkpoint Inhibitors: Overview and Clinical Applications
Immunotherapy - Checkpoint Inhibitors: Overview and Clinical Applications Views - 2
Immunotherapy - Chimeric Antigen Receptor (CAR) T Cells - Overview and Clinical Applications
Immunotherapy - Chimeric Antigen Receptor (CAR) T Cells - Overview and Clinical Applications Views - 2
It is a Big Deal: Obesity and Cancer
It is a Big Deal: Obesity and Cancer Views - 4
Oncology Nursing Science
Oncology Nursing Science Views - 7
Phase IIIB Randomized Study of Lenalidomide Plus Rituximab Followed By Maintenance in Relapsed/Refractory NHL
Phase IIIB Randomized Study of Lenalidomide Plus Rituximab Followed By Maintenance in Relapsed/Refractory NHL Views - 7
Phase IB/II Study of Nivolumab with Azacytidine in Patients with Relapsed AML
Phase IB/II Study of Nivolumab with Azacytidine in Patients with Relapsed AML Views - 2
Tolerability and Activity of Chemo-free Triplet Combination of TGR-1202 (Ublituximab) and Ibrutinib in Advanced CLL and NHL
Tolerability and Activity of Chemo-free Triplet Combination of TGR-1202 (Ublituximab) and Ibrutinib in Advanced CLL and NHL Views - 9
Ublituximab and Ibrutinib for Previously Treated Genetically High-Risk CLL: Results of the GENUINE Study
Ublituximab and Ibrutinib for Previously Treated Genetically High-Risk CLL: Results of the GENUINE Study Views - 3
First-line Treatment of iNHL or MCL Patients with BR or R-CHOP/R-CVP: BRIGHT 5-year Follow-up Study
First-line Treatment of iNHL or MCL Patients with BR or R-CHOP/R-CVP: BRIGHT 5-year Follow-up Study Views - 5
WT1 Heteroclitic Epitope Immunization Following ASCT in Patients with High-Risk Multiple Myeloma
WT1 Heteroclitic Epitope Immunization Following ASCT in Patients with High-Risk Multiple Myeloma Views - 3
RAD versus VRd Prior to SCT in Newly Diagnosed Myeloma
RAD versus VRd Prior to SCT in Newly Diagnosed Myeloma Views - 4
Phase I/II Trial of Glasdegib in Patients With Primary or Secondary Myelofibrosis
Phase I/II Trial of Glasdegib in Patients With Primary or Secondary Myelofibrosis Views - 3
Phase 3 Trial of Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Phase 3 Trial of Momelotinib versus Best Available Therapy in Patients with Myelofibrosis Previously Treated with Ruxolitinib Views - 5
Phase 3 Trial of Momelotinib versus Ruxolitinib in JAK Inhibitor Naive Patients with Myelofibrosis
Phase 3 Trial of Momelotinib versus Ruxolitinib in JAK Inhibitor Naive Patients with Myelofibrosis Views - 5
Bosutinib versus Imatinib for Newly Diagnosed CML: Initial Results from the BFORE Trial
Bosutinib versus Imatinib for Newly Diagnosed CML: Initial Results from the BFORE Trial Views - 6
FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy in Stage III Colon Cancer (ATOMIC)
FOLFOX Alone or Combined with Atezolizumab as Adjuvant Therapy in Stage III Colon Cancer (ATOMIC) Views - 10
Association of MSI status and mutational load with overall survival in mCRC of CALGB/SWOG 80405 (ALLIANCE)
Association of MSI status and mutational load with overall survival in mCRC of CALGB/SWOG 80405 (ALLIANCE) Views - 5
Pembrolizumab plus 5-FU and Cisplatin for First-line Treatment in Advanced Gastric Cancer (KEYNOTE-059)
Pembrolizumab plus 5-FU and Cisplatin for First-line Treatment in Advanced Gastric Cancer (KEYNOTE-059) Views - 6
Pages:
1 2 3 4 5 6 7 8 9 10 11
... Next
ABOUT ONCOLOGY.TV

Oncology.TV offers physicians, nurses, and other healthcare professionals the timeliest comprehensive and relevant clinical information to improve patient care. We provide medical education (both free CE and non CE, including interactive case based presentations), and other news and information on a variety of tumor types.

SOCIAL MEDIA
OTHER ONCOLOGY.TV SITES 

 
 

PARTNER SITES
 
Privacy Statement  |   Terms Of Use  |  Contact Oncology.TV  |   Copyright 2017 by Oncology.TV